Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $14.92, for a total transaction of $89,520.00. Following the sale, the executive vice president now directly owns 362,080 shares in the company, valued at $5,402,233.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Christopher Haqq also recently made the following trade(s):
- On Thursday, June 15th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $12.65, for a total transaction of $75,900.00.
Shares of Atara Biotherapeutics, Inc. (ATRA) opened at 15.30 on Monday. Atara Biotherapeutics, Inc. has a 52-week low of $11.80 and a 52-week high of $25.73. The company has a 50 day moving average of $14.69 and a 200 day moving average of $15.88. The firm’s market capitalization is $445.37 million.
WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/07/christopher-haqq-sells-6000-shares-of-atara-biotherapeutics-inc-nasdaqatra-stock-updated-updated.html.
Several research firms have issued reports on ATRA. ValuEngine cut shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $25.75.
Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in Atara Biotherapeutics during the fourth quarter valued at $4,031,000. State Street Corp boosted its position in Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the biotechnology company’s stock valued at $8,526,000 after buying an additional 231,541 shares during the period. EcoR1 Capital LLC boosted its position in Atara Biotherapeutics by 101.5% in the first quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock valued at $8,935,000 after buying an additional 219,000 shares during the period. Goldman Sachs Group Inc. boosted its position in Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock valued at $4,135,000 after buying an additional 173,184 shares during the period. Finally, Eagle Asset Management Inc. boosted its position in Atara Biotherapeutics by 14.1% in the first quarter. Eagle Asset Management Inc. now owns 1,267,609 shares of the biotechnology company’s stock valued at $26,049,000 after buying an additional 156,911 shares during the period. 81.50% of the stock is currently owned by institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
